Background: Ozanimod, a selective sphingosine-1-phosphate receptor modulator, has been approved for the treatment of moderately to severely active ulcerative colitis (UC) and relapsing forms of multiple sclerosis (MS). However, i... ...

请注册登录后继续浏览